Drug Trial Radar · NCT06137742
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
97
Actual
Start
Nov 17, 2023
Primary completion
Jul 31, 2026
Study completion Jul 31, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH). Part A: An investigator- and participant-blind, sponsor-open, placebo-controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics (PK) of PF-07868489 in healthy adult participants. Part B: A 24-week, randomized, double blind, placebo-controlled study to assess the safety, tolerability, PK, and pharmacodynamics (PD) of PF-07868489 in adult participants with PAH.
Conditions
- Pulmonary Arterial Hypertension
Interventions
PF-07868489Drug
Experimental Treatment
Placebo for PF-07868489Drug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to Day 113.
- Number of Participants With Change From Baseline in Laboratory Tests ResultsTime frame: Baseline up to Day 113
- Number of Participants With Vital Sign AbnormalitiesTime frame: Baseline up to Day 113
- Number of Participants With Change From Baseline in Electrocardiogram (ECG) ParametersTime frame: Baseline up to Day 113
- Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to Day 253
- Number of Participants With Change From Baseline in Laboratory Tests ResultsTime frame: Baseline up to Day 253
- Number of Participants With Vital Sign AbnormalitiesTime frame: Baseline up to Day 253
- Number of Participants With Change From Baseline in Electrocardiogram (ECG) ParametersTime frame: Baseline up to Day 253
- Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week24Time frame: Baseline, Week 24
Locations
46 sites in 12 countries. Site status is shown where the registry gives one.
Anaheim Clinical Trials, LLC
Anaheim, California
UCI Health - Costa Mesa
Costa Mesa, California
UCI Health Center for Innovative Health Therapies (CIHT)
Orange, California
University of California, Irvine Medical Center
Orange, California
UCSF Health St. Mary's Hospital
San Francisco, California
UCSF Helen Diller Medical Center at Parnassus Heights
San Francisco, California
Icahn school of medicine at Mount Sinai
New York, New York
Mount Sinai Hospital
New York, New York
Eastowne 100 Medical Office Building
Chapel Hill, North Carolina
Eastowne Medical Office Building - Clinical Research Unit
Chapel Hill, North Carolina
UNC Health - Eastowne Medical Office
Chapel Hill, North Carolina
UNC Hospitals
Chapel Hill, North Carolina
Investigational Drug Services Pharmacy
Morrisville, North Carolina
Medical University of South Carolina - Nexus
Charleston, South Carolina
Medical University of South Carolina - Radiology
Charleston, South Carolina
Medical University of South Carolina
Charleston, South Carolina
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Pulmonary Hypertension Research Queensland Pty Ltd
Auchenflower, Queensland, Australia
Wesley Research Institute
Auchenflower, Queensland, Australia
Université Libre de Bruxelles - Hôpital Erasme
Brussels, Bruxelles-capitale, Région de, Belgium
UZ Leuven
Leuven, Vlaams-brabant, Belgium
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Vseobecna fakultni nemocnice v Praze
Prague, Czechia
CHRU de Brest
Brest, Finistère, France
CHRU de Brest
Brest, Finistère, France
Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord
Saint Priest En Jarez, Pays de la Loire Region, France
Thoraxklinik-Heidelberg gGmbH
Heidelberg, Baden-Wurttemberg, Germany
Universitätsklinikum Regensburg
Regensburg, Bavaria, Germany
UKGM Gießen/Marburg
Giessen, Hesse, Germany
Universitätsmedizin Greifswald
Greifswald, Mecklenburg-Vorpommern, Germany
Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden
Dresden, Saxony, Germany
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
National Hospital Organization Okayama Medical Center
Okayama, Japan
Kobe University Hospital
Kobe, Hyōgo, Japan
St. Marianna University Hospital
Kawasaki, Kanagawa, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Gachon University Gil Medical Center
Namdong-gu, Incheon-gwangyeoksi [incheon], South Korea
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.